|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
|
15588467 |
2004 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
PAI-1 activity elevation remained in PCOS women with mean fasting insulin levels < 10 mIU/ml (p = 0.02), yet the difference became less significant when insulin was controlled (p = 0.38).
|
12857431 |
2003 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
2) PCOS women have higher levels of PAI-1 compared with the control group.
|
15191349 |
2004 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Together with low birth weight, increased plasma PAI-1-act levels in early pubertal PP girls may indicate those girls with greater risk of developing hyperinsulinemic-hyperandrogenism features of PCOS.
|
11809921 |
2002 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PAI-1 gene 4G polymorphism is more common in women with PCOS than in normal women and, in concert with obesity, hyperinsulinemia, and hypertriglyceridemia, contributes to treatable, hypofibrinolytic, miscarriage-promoting, high PAI-1 activity.
|
16483878 |
2006 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We noted differences in the ovarian distribution of PAI-1 that was expressed throughout the PCOS ovary, unlike the peripheral distribution observed in control ovaries.
|
30878040 |
2019 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The plasminogen activator system in young and lean women with polycystic ovary syndrome.
|
15516780 |
2004 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Statin and insulin-sensitizing drugs may provide a potential therapy for PCOS via down-regulation of PAI-1 expression in GCs and down-regulation of TGF-β and TNF-α expression in PFMC, respectively.
|
28337819 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
LHGDN |
Plasminogen activator inhibitor-1 (PAI-1), the main physiological inhibitor of plasminogen activation, is consistently elevated in women with PCOS, regardless of metabolic status.
|
17601881 |
2007 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with PCOS had elevated PAI-1, sVCAM-1 and sICAM-1 before and after weight loss compared with the controls.
|
22995747 |
2012 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polycystic ovarian syndrome (PCOS) is associated with insulin-induced plasminogen activator inhibitor-1 (PAI-1) elevations.
|
11821270 |
2002 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1), the main physiological inhibitor of plasminogen activation, is consistently elevated in women with PCOS, regardless of metabolic status.
|
17601881 |
2007 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was aimed to report the impact of six-month OCP use on plasminogen activator inhibitor-1 (PAI-1) and factor VIII (FVIII) in women with PCOS.
|
30964093 |
2018 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
LHGDN |
Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome.
|
18029284 |
2008 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.
|
24435452 |
2014 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
4 G allele in PAI-1 gene was more frequent in PCOS and the 4G/4 G genotype was associated with increased PAI-1 levels.
|
23898913 |
2013 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 levels are positively associated with the syndrome, and carriers of the 4G allele of the 4G/5G polymorphism are at risk of developing PCOS.
|
22553983 |
2012 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for ACE D or PAI-1 4G polymorphisms as well as compound carrier status are significant positive explanatory variable for PCOS patients with SAB, which may result in increased PAI-1 concentrations and hypofibrinolysis and contribute to early pregnancy loss.
|
19636212 |
2010 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To compare cardiac risk markers such as asymmetric dimethyl arginine (ADMA), C-reactive protein (CRP), homocystein (Hcy), plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF), angiopoietin-related growth factor 6 (ANGPTL6) in obese and non-obese patients with polycystic ovary syndrome (PCOS).
|
27425379 |
2017 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A trend to a positive interaction between PAI-1 -675 4G/5G and -844 A/G gene polymorphism may elevate plasma PAI-1 levels and hypofibrinolysis, which is probably an important hereditary risk factor in PCOS.
|
19856137 |
2009 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our pooled data suggest evidence for a major role of PAI-1 gene 4G/5G polymorphism in the pathogenesis of PCOS among Chinese patients.
|
25731152 |
2015 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.
|
17661167 |
2007 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GDM and PCOS are related to the genetic role of the 4G/5G polymorphism of <i>PAI-1</i>.
|
28758928 |
2017 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
2) PCOS women have higher levels of PAI-1 compared with the control group.
|
15191349 |
2004 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results showed the significance of MTHFR A1298C and PAI-1 4G/5G mutations in Iranian women suffering from RPL with and without PCOS.
|
22882325 |
2012 |